These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8006400)

  • 1. High doses of aminoglycosides did not produce liver toxicity in patients with cystic fibrosis.
    Lindblad A; Hultcrantz R; Strandvik B
    J Hepatol; 1994 Feb; 20(2):201-5. PubMed ID: 8006400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
    McRorie TI; Bosso J; Randolph L
    Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Tan K; Bunn H
    Cochrane Database Syst Rev; 2000; (4):CD002009. PubMed ID: 11034740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Tan KH
    Cochrane Database Syst Rev; 2006 Jul; (3):CD002009. PubMed ID: 16855982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.
    Horrevorts AM; Driessen OM; Michel MF; Kerrebijn KF
    Chest; 1988 Aug; 94(2 Suppl):120S-125S. PubMed ID: 3293937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.
    Kovesi TA; Swartz R; MacDonald N
    N Engl J Med; 1998 Jan; 338(1):65-6. PubMed ID: 9424574
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal impairment following aminoglycoside therapy in cystic fibrosis.
    Tai A
    Thorax; 2008 Oct; 63(10):936; author reply 936-7. PubMed ID: 18820124
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
    Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
    Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successive courses of intensive therapy in cystic fibrosis (author's transl)].
    Feigelson J; Pecau Y; Gaultier C; Boule M; Høiby N
    Nouv Presse Med; 1981 Mar; 70(12):955-8. PubMed ID: 7208319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycosides, toxicity and cystic fibrosis.
    Watson AR
    J R Soc Med; 2007; 100 Suppl 47():24-8. PubMed ID: 17926725
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.
    Handelsman JA; Nasr SZ; Pitts C; King WM
    Pediatr Pulmonol; 2017 Sep; 52(9):1157-1162. PubMed ID: 28737283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
    Soulsby N; Bell S; Greville H; Doecke C
    Intern Med J; 2009 Aug; 39(8):527-31. PubMed ID: 19220547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
    Alghanem S; Paterson I; Touw DJ; Thomson AH
    J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Smyth A; Knox A; Baldwin D; Mulheran M
    Arch Dis Child; 1999 Feb; 80(2):207-8. PubMed ID: 10325748
    [No Abstract]   [Full Text] [Related]  

  • 18. Feasibility and cost savings of intravenous administration of aminoglycosides in outpatients with cystic fibrosis.
    Bosso JA; Stephenson SE; Herbst JJ
    Drug Intell Clin Pharm; 1985 Jan; 19(1):52-4. PubMed ID: 3967575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case-control study of acute renal failure in patients with cystic fibrosis in the UK.
    Smyth A; Lewis S; Bertenshaw C; Choonara I; McGaw J; Watson A
    Thorax; 2008 Jun; 63(6):532-5. PubMed ID: 18245146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.
    Lindsay CA; Bosso JA
    Clin Pharmacokinet; 1993 Jun; 24(6):496-506. PubMed ID: 8513651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.